Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Semler Scientific ( (SMLR) ) has shared an update.
On June 24, 2025, Semler Scientific announced the creation of CardioVanta, Inc., a wholly-owned subsidiary dedicated to its future healthcare business activities. This strategic move aims to enhance the company’s focus on early detection of heart-related conditions and involves seeking external investment to support its initial capital requirements, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (SMLR) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Semler Scientific stock, see the SMLR Stock Forecast page.
Spark’s Take on SMLR Stock
According to Spark, TipRanks’ AI Analyst, SMLR is a Neutral.
Semler Scientific faces significant financial challenges, with declining revenue and profitability, and negative cash flow. While technical analysis shows some short-term bullish momentum, valuation metrics point to potential overvaluation concerns. The earnings call reveals mixed sentiment with ambitious growth strategies, particularly in bitcoin, but overshadowed by financial setbacks. Recent corporate events highlight strategic efforts to enhance shareholder value, contributing positively to the overall score.
To see Spark’s full report on SMLR stock, click here.
More about Semler Scientific
Semler Scientific operates in the healthcare industry, focusing on products and services related to the early detection of heart failure and cardiac arrhythmia monitoring.
Average Trading Volume: 876,106
Technical Sentiment Signal: Sell
Current Market Cap: $403M
See more insights into SMLR stock on TipRanks’ Stock Analysis page.